Durata Therapeutics Prices Public Offering of Common Stock
CHICAGO, April 12, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced the pricing of an underwritten public offering
of 7,150,000 shares of its common stock at a public offering price of $7.00
per share, before underwriting discounts. In addition, the underwriters have
an option for a period of 30 days to purchase up to an additional 1,072,500
shares of common stock from Durata at the public offering price less the
All of the shares in the offering are to be sold by Durata, with expected net
proceeds to Durata of approximately $46.3 million after deducting underwriting
discounts and commissions and estimated offering expenses. The offering is
expected to close on or about April 17, 2013.
BofA Merrill Lynch, Credit Suisse Securities (USA) LLC and Jefferies LLC are
acting as joint book-running managers for the offering, and JMP Securities LLC
and RBC Capital Markets, LLC are acting as co-managers.
A registration statement relating to the securities being sold in this
offering was declared effective by the Securities and Exchange Commission on
April 11, 2013. The offering is being made only by means of a prospectus,
copies of which may be obtained by contacting BofA Merrill Lynch by mail at
222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by e-mail at
firstname.lastname@example.org; Credit Suisse Securities (USA) LLC by mail at
One Madison Avenue, New York, NY 10010, Attn: Prospectus Department, by e-mail
at email@example.com, or by telephone at 1-800-221-1037; or
Jefferies LLC by mail at 520 Madison Avenue, New York, New York 10022, Attn:
Equity Syndicate Prospectus Department, by e-mail at
Prospectus_Department@Jefferies.com, or by telephone at 1-877-547-6340.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of such state or jurisdiction.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.
CONTACT: Allison Wey
Durata Therapeutics, Inc.
Vice President, Investor Relations and Public Affairs
Durata Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.